Swiss - Delayed Quote CHF
Spexis AG (SPEX.SW)
At close: July 31 at 5:33 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
21,305.0030
21,305.0030
20,141.5430
4,248.2250
1,276.8750
Operating Income
-21,305.0030
-21,305.0030
-20,141.5430
-4,248.2250
-1,276.8750
Net Non Operating Interest Income Expense
-762.3990
-762.3990
-150.1230
-1,442.4410
-679.1300
Pretax Income
-19,618.8670
-19,618.8670
-18,553.0020
-11,861.5930
-1,851.3050
Net Income Common Stockholders
-19,618.8680
-19,618.8680
-18,553.0020
-11,861.5920
-1,851.3050
Diluted NI Available to Com Stockholders
-19,618.8680
-19,618.8680
-18,553.0020
-11,861.5920
-1,851.3050
Basic EPS
-0.37
-0.37
-0.38
-0.82
-0.14
Diluted EPS
-0.37
-0.37
-0.38
-0.82
-0.14
Basic Average Shares
53,012.5260
53,012.5260
48,197.6500
14,545.7140
12,912.0180
Diluted Average Shares
53,012.5260
53,012.5260
48,197.6500
14,545.7140
12,912.0180
Total Operating Income as Reported
-20,549.8550
-20,549.8550
-18,666.4110
-4,247.8940
-1,224.5410
Total Expenses
21,305.0030
21,305.0030
20,141.5430
4,248.2250
1,276.8750
Net Income from Continuing & Discontinued Operation
-19,618.8680
-19,618.8680
-18,553.0020
-11,861.5920
-1,851.3050
Normalized Income
-19,580.8010
-19,580.8010
-18,553.0020
-5,718.6700
-1,851.0340
Interest Income
173.5870
173.5870
13.3970
--
26.1460
Interest Expense
935.0050
935.0050
163.4120
671.9990
705.2760
Net Interest Income
-762.3990
-762.3990
-150.1230
-1,442.4410
-679.1300
EBIT
-18,683.8620
-18,683.8620
-18,389.5900
-11,189.5940
-1,146.0290
EBITDA
-17,791.3910
-17,791.3910
-16,971.0760
-11,176.3910
-1,146.0290
Reconciled Depreciation
892.4710
892.4710
1,418.5140
13.2030
--
Net Income from Continuing Operation Net Minority Interest
-19,618.8680
-19,618.8680
-18,553.0020
-11,861.5920
-1,851.3050
Total Unusual Items Excluding Goodwill
-38.0670
-38.0670
--
-6,142.9220
-0.2710
Total Unusual Items
-38.0670
-38.0670
--
-6,142.9220
-0.2710
Normalized EBITDA
-17,753.3240
-17,753.3240
-16,971.0760
-5,033.4690
-1,145.7580
12/31/2020 - 5/15/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NWRN.SW Newron Pharmaceuticals S.p.A.
7.78
+0.78%
ADXN.SW Addex Therapeutics Ltd
0.0850
+2.41%
MOLN.SW Molecular Partners AG
5.20
-6.14%
BSLN.SW Basilea Pharmaceutica AG
42.50
-0.23%
VVY.AS Vivoryon Therapeutics N.V.
2.1900
-2.88%
SANN.SW Santhera Pharmaceuticals Holding AG
8.80
+1.27%
MOLN Molecular Partners AG
6.03
+0.33%
IDIA.SW Idorsia Ltd
0.9600
+4.07%
ADXN Addex Therapeutics Ltd
10.64
-5.59%
MNOV MediciNova, Inc.
1.5700
+0.64%